First results of a new add-on IOL for pseudophakic patients with macular degeneration

Session Details

Session Title: Presented Poster Session: Cataract Complications & Special Cases

Venue: Poster Village: Pod 1

First Author: : F.Badala ITALY

Co Author(s): :    E. Bona                       

Abstract Details

Purpose:

To determine safety and efficacy of a new intraocular add-on IOL, EyeMax mono (London Eye Hospital Pharma; London, UK) in pseudophakic patients with dry and stable wet macular degeneration (AMD). The EyeMax mono add-on IOL is an injectable hydrophilic acrylic IOL implanted in the sulcus in pseudophakic patients.

Setting:

Micro Chirurgia Oculare Milano

Methods:

A prospective case series of 17 pseudophakic eyes (11 patients) with dry or stable wet AMD that underwent EyeMax mono add-on IOL implantation in the sulcus and had at least 4 months follow-up. Outcomes were distant and near visual acuity, intra- and postoperative complications. The EyeMax add-on IOL is an injectable hydrophilic acrylic IOL designed to improve the quality of the retinal image in all areas of the macula up to 10 degrees from fixation and generate a moderate hypermetropic correction for magnification.

Results:

Visual acuity improved in all patients, for both distance (mean gain: 11 ETDRS letters) and near (mean gain: 15 ETDRS letters). Patients implanted bilaterally had the best visual outcome. All patients experienced an hyperopic shift of +2.5 of their manifest refraction. No intra- or postop complications were encountered.

Conclusions:

The EyeMax mono add-on IOL shows promising results in improving distance and near vision in pseudophakic eyes with macular degeneration. Near visual acuity seems to benefit more than distance visual acuity. Patients implanted bilaterally seems to get a better outcome.

Financial Disclosure:

None